Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial

Arthritis & RheumatologyVolume 73, Issue 5 p. 721-724 Notes From the Field Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial Hyon K. Choi, Corresponding Author Hyon K. Choi [email protected] Massachusetts General Hospital, Boston Address correspondence to Hyon Choi, MD, DrPH, Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, 55 Fruit Street, Boston, MA 02114 (email: [email protected]); or to Nicola Dalbeth, MBChB, MD, FRACP, University of Auckland, Department of Medicine, Faculty of Medical and Health Sciences, 85 Park Road, Grafton, Auckland 1023, New Zealand (email: [email protected]).Search for more papers by this authorTuhina Neogi, Tuhina Neogi orcid.org/0000-0002-9515-1711 Boston University School of Medicine, Boston, MassachusettsSearch for more papers by this authorLisa K. Stamp, Lisa K. Stamp orcid.org/0000-0003-0138-2912 University of Otago, Christchurch, New ZealandSearch for more papers by this authorRobert Terkeltaub, Robert Terkeltaub orcid.org/0000-0001-5368-7473 VA San Diego Healthcare System and University of California San DiegoSearch for more papers by this authorNicola Dalbeth, Corresponding Author Nicola Dalbeth [email protected] orcid.org/0000-0003-4632-4476 University of Auckland, Auckland, New Zealand Address correspondence to Hyon Choi, MD, DrPH, Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, 55 Fruit Street, Boston, MA 02114 (email: [email protected]); or to Nicola Dalbeth, MBChB, MD, FRACP, University of Auckland, Department of Medicine, Faculty of Medical and Health Sciences, 85 Park Road, Grafton, Auckland 1023, New Zealand (email: [email protected]).Search for more papers by this author Hyon K. Choi, Corresponding Author Hyon K. Choi [email protected] Massachusetts General Hospital, Boston Address correspondence to Hyon Choi, MD, DrPH, Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, 55 Fruit Street, Boston, MA 02114 (email: [email protected]); or to Nicola Dalbeth, MBChB, MD, FRACP, University of Auckland, Department of Medicine, Faculty of Medical and Health Sciences, 85 Park Road, Grafton, Auckland 1023, New Zealand (email: [email protected]).Search for more papers by this authorTuhina Neogi, Tuhina Neogi orcid.org/0000-0002-9515-1711 Boston University School of Medicine, Boston, MassachusettsSearch for more papers by this authorLisa K. Stamp, Lisa K. Stamp orcid.org/0000-0003-0138-2912 University of Otago, Christchurch, New ZealandSearch for more papers by this authorRobert Terkeltaub, Robert Terkeltaub orcid.org/0000-0001-5368-7473 VA San Diego Healthcare System and University of California San DiegoSearch for more papers by this authorNicola Dalbeth, Corresponding Author Nicola Dalbeth [email protected] orcid.org/0000-0003-4632-4476 University of Auckland, Auckland, New Zealand Address correspondence to Hyon Choi, MD, DrPH, Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, 55 Fruit Street, Boston, MA 02114 (email: [email protected]); or to Nicola Dalbeth, MBChB, MD, FRACP, University of Auckland, Department of Medicine, Faculty of Medical and Health Sciences, 85 Park Road, Grafton, Auckland 1023, New Zealand (email: [email protected]).Search for more papers by this author First published: 05 January 2021 https://doi.org/10.1002/art.41638Citations: 7 Dr. Choi has received consulting fees from Takeda and Selecta (less than $10,000 each) and research support from Horizon. Dr. Neogi has received consulting fees from Arthrosi (less than $10,000). Dr. Terkeltaub has received consulting fees from AstraZeneca, Horizon, Genentech, and Sobi (less than $10,000 each) and from Selecta (more than $10,000). Dr. Dalbeth has received consulting fees, speaking fees, and/or honoraria from AstraZeneca, Dyve, Selecta, Horizon, Arthrosi, Cello Health, AbbVie, and Janssen (less than $10,000 each). No other disclosures relevant to this article were reported. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume73, Issue5May 2021Pages 721-724 RelatedInformation